248 related articles for article (PubMed ID: 29753121)
1. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
Armato SG; Nowak AK
J Thorac Oncol; 2018 Jul; 13(7):1012-1021. PubMed ID: 29753121
[TBL] [Abstract][Full Text] [Related]
2. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
Byrne MJ; Nowak AK
Ann Oncol; 2004 Feb; 15(2):257-60. PubMed ID: 14760119
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
4. CT, RECIST, and malignant pleural mesothelioma.
Nowak AK
Lung Cancer; 2005 Jul; 49 Suppl 1():S37-40. PubMed ID: 15950799
[TBL] [Abstract][Full Text] [Related]
5. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
van Klaveren RJ; Aerts JG; de Bruin H; Giaccone G; Manegold C; van Meerbeeck JP
Lung Cancer; 2004 Jan; 43(1):63-9. PubMed ID: 14698538
[TBL] [Abstract][Full Text] [Related]
6. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
Buikhuisen WA; Qayyum F; Armato SG; Baas P
Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
[No Abstract] [Full Text] [Related]
7. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
[TBL] [Abstract][Full Text] [Related]
8. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
Monetti F; Casanova S; Grasso A; Cafferata MA; Ardizzoni A; Neumaier CE
Lung Cancer; 2004 Jan; 43(1):71-4. PubMed ID: 14698539
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor response in malignant pleural mesothelioma.
Ceresoli GL; Chiti A; Zucali PA; Cappuzzo F; De Vincenzo F; Cavina R; Rodari M; Poretti D; Lutman FR; Santoro A
Cancer Treat Rev; 2007 Oct; 33(6):533-41. PubMed ID: 17764849
[TBL] [Abstract][Full Text] [Related]
10. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Li F; Ahmad M; Qayyum F; Straus CM; MacMahon H; Kindler H; Armato SG
Eur Radiol; 2019 Jun; 29(6):2981-2988. PubMed ID: 30617480
[TBL] [Abstract][Full Text] [Related]
11. Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions.
Armato SG; Nowak AK; Francis RJ; Kocherginsky M; Byrne MJ
J Thorac Oncol; 2014 Aug; 9(8):1187-94. PubMed ID: 25157772
[TBL] [Abstract][Full Text] [Related]
12. The role of volumetric method in the assessment of chemotherapy response and predicting survival in malignant pleural mesothelioma.
Urfali FE; Metintas S; Gurgen A; Guntulu AK; Ozkan R; Metintas M
J Cancer Res Ther; 2021; 17(1):69-74. PubMed ID: 33723135
[TBL] [Abstract][Full Text] [Related]
13. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.
Tsao AS; Garland L; Redman M; Kernstine K; Gandara D; Marom EM
J Thorac Oncol; 2011 Mar; 6(3):598-601. PubMed ID: 21270668
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
17. Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
Armato SG; Blyth KG; Keating JJ; Katz S; Tsim S; Coolen J; Gudmundsson E; Opitz I; Nowak AK
Lung Cancer; 2016 Nov; 101():48-58. PubMed ID: 27794408
[TBL] [Abstract][Full Text] [Related]
18. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
Vivoda Tomšič M; Bisdas S; Kovač V; Serša I; Šurlan Popovič K
Cancer Imaging; 2019 Feb; 19(1):10. PubMed ID: 30813957
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
